Polivy Chemoimmunotherapy Regimen Approved to Treat DLBCL

TUESDAY, June 11, 2019 — Polivy (polatuzumab vedotin-piiq), a novel antibody-drug conjugate, received approval to treat patients with diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab, the U.S. Food and Drug…
Source: Topamax